Communication on the association of MabThera® (Rituximab) with fatal infusion related reactions in patients with Rheumatoid arthritis

Roche, in consultation with HSA, is informing healthcare professionals about new safety information on the use of MabThera®(Rituximab) in rheumatoid arthritis. Since the marketing approval of MabThera® for use in rheumatoid arthritis, Roche has received postmarketing reports of fatal infusion related reactions with the use of the medicine. Healthcare professionals are advised to follow the recommendations provided in this Dear Healthcare Professional Letter when using the product, including being vigilant for signs of hypersensitivity or anaphylaxis.

 
 
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP), a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.hpp.moh.gov.sg and follow the procedures below to access the MOH Alert system.

Step 1: Select your profession under 'For Healthcare Professionals’.

Step 2: Click on 'Restricted Content' and log in via SingPass.

Step 3: Click on the MOH Alert icon under ‘Applications’.

Step 4: Click on the Drug Alert tab to view the DHCPLs.